Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesFinished GoodsGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsPayablesPreferred Stock LiabilitiesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Rhythm Pharmaceuticals (RYTM) Operating Leases (2021 - 2025)

Rhythm Pharmaceuticals (RYTM) has disclosed Operating Leases for 5 consecutive years, with $3.3 million as the latest value for Q4 2025.

  • Quarterly Operating Leases fell 15.13% to $3.3 million in Q4 2025 from the year-ago period, while the trailing twelve-month figure was $3.3 million through Dec 2025, down 15.13% year-over-year, with the annual reading at $3.3 million for FY2025, 15.13% down from the prior year.
  • Operating Leases for Q4 2025 was $3.3 million at Rhythm Pharmaceuticals, down from $3.5 million in the prior quarter.
  • The five-year high for Operating Leases was $4.0 million in Q3 2024, with the low at $284000.0 in Q1 2024.
  • Average Operating Leases over 5 years is $2.2 million, with a median of $1.8 million recorded in 2021.
  • The sharpest move saw Operating Leases tumbled 73.61% in 2024, then skyrocketed 1251.76% in 2025.
  • Over 5 years, Operating Leases stood at $1.9 million in 2021, then crashed by 35.22% to $1.3 million in 2022, then tumbled by 61.11% to $490000.0 in 2023, then surged by 703.67% to $3.9 million in 2024, then decreased by 15.13% to $3.3 million in 2025.
  • According to Business Quant data, Operating Leases over the past three periods came in at $3.3 million, $3.5 million, and $3.7 million for Q4 2025, Q3 2025, and Q2 2025 respectively.